Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

iShares MSCI Taiwan ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI Taiwan ETF trades at $106.32, while Regeneron Pharmaceuticals Inc trades at $793.06 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals.

EWTREGN
Sector
Broad Market / FactorHealth
52-Week High
$111.53$812.27
52-Week Low
$58.05$555.51
Market Cap
$82.06B
Enterprise Value
$76.77B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.

Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN